AAP: Risk Behaviors Relatively Common in Gender Diverse Youth
New research was presented at AAP 2020, the 2020 American Academy of Pediatrics Virtual National...
Read MoreOct 12, 2020
New research was presented at AAP 2020, the 2020 American Academy of Pediatrics Virtual National...
Read MoreOct 2, 2020
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreOct 2, 2020
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read MoreOct 2, 2020
Neurite orientation dispersion and density imaging (NODDI) can detect brain microstructural and metabolic alterations after the first demyelinating event in MS [1]. There was increased axonal dispersion in normal-appearing white...
Read MoreOct 2, 2020
People with MS are not more susceptible to COVID-19 infection than the UK general population, suggest results of the largest community-based study of COVID-19 in people with MS worldwide [1]. During lockdown, with strict...
Read MoreOct 2, 2020
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreOct 2, 2020
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreOct 2, 2020
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Read MoreOct 2, 2020
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...
Read MoreOct 2, 2020
Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...
Read MoreOct 2, 2020
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreOct 2, 2020
For one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...
Read MoreOct 2, 2020
In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read MoreOct 2, 2020
Only a few weeks prior to MSVirtual2020, the fully human anti-CD20 monoclonal antibody ofatumumab...
Read MoreSep 24, 2020
Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...
Read MoreSep 24, 2020
Most patients with metastatic urothelial cancer respond to first-line chemotherapy but relapse...
Read MoreSep 24, 2020
Both CheckMate-649 and ATTRACTION-4 showed a statistically significant improvement in...
Read MoreSep 24, 2020
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...
Read MoreSep 24, 2020
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....
Read MoreSep 24, 2020
While many patients with hormone receptor (HR)-positive and human epidermal growth factor receptor...
Read More